Molecular Tri-Con 2017 was another great meeting for Horizon Discovery with a fantastic buzz surrounding all our activities.
Product Launch: Multiplex I cfDNA Reference Standard Set
Developed using clinically-relevant mutations, the Multiplex I cfDNA Reference Standard Set in Synthetic Plasma contains eight cancer-relevant mutations including BRAF, EGFR, KRAS, NRAS, and PIK3CA at 5%, 1%, and 0.1% allelic frequencies. These mutations are associated with multiple forms of cancer including breast, colorectal, pancreatic and particularly lung, where one specific mutation covered in the panel, EGFR T790M, is associated with Iressa® (Gefitinib) resistance.
By engineering the reference standard in plasma, full understanding of assay performance from extraction and quantification through to analysis and informatics is possible, mimicking the challenges of dealing with human material.
Seminar Talk: Enabling Sequencing Technologies to Reach Their Full Potential – Bringing ctDNA to the Clinic
At Molecular Tri-Con 2017, Davina Gale, co-founder of Inivata Ltd and a customer of Horizon Discovery’s Tru-Q product range presented on:
- The use of NGS for molecular profiling of circulating tumor DNA (ctDNA) as a non-invasive ‘liquid biopsy’
- InVision® technology: Enhanced TAm-Seq assay for broad molecular profiling
- How to develop a clinical NGS assay and the importance of quantitative reference standards
- The analytical validation of InVision using Tru-Q HDx Reference Standards from Horizon Discovery
- The clinical performance of InVision
In conclusion, the use of Horizon’s Reference Standards allows Inivata to demonstrate accurate and reliable data using InVision technology, down to low MAFs (0.1%) that would have previously have been missed using other types of technologies.